Assessing the Latest Safety and Efficacy Data for New and Emerging Therapies in the Treatment of Acute Heart Failure

This program is developed through a collaborative partnership between Antidote Education Company and ArcheMedX.

This CME activity is supported by an educational grant from Novartis.

Scroll to the Bottom of this Information to Begin this Course

Release date: March 19, 2015

Valid through: March 19, 2016

Specialty: Cardiology

Topic: Acute Heat Failure

Media: Internet

Estimated Time to Complete Activity: 45 minutes

Target Audience

This program is designed for emergency department physicians and residents, hospitalists and cardiologists involved in the care of patients with acute heart failure.

Program Overview

This session is the last of a three part series on providing a clinical update on the management of acute decompensated heart failure.  Dr. Ileana Piña will provide a survey of the latest safety and efficacy data for new therapies.  She will also discuss emerging therapies and how the new mechanisms are influencing the way AHF is treated.  The panel will engage in a lively discussion of the best approaches to take in managing AHF and how the manage medications in transitioning a patient from acute to chronic heart failure.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Compare and contrast new and emerging therapies for ADHF through assessment of clinical trial data

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Program Chair

William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
Professor of Internal Medicine, Physiology and Cell Biology Chair of Excellence in Cardiovascular
Medicine Chief, Division of Cardiovascular Medicine Associate Dean for Clinical Research
Medical Director, Clinical Trials Management Office, The Ohio State University Columbus, OH

For Dr. Abraham's biography, click here


Presenting Faculty

Ileana L. Piña, MD, MPH
Professor of Medicine and Epidemiology & Population Health and Vice Chief for Academic Affairs,
Albert Einstein College of Medicine and Montefiore Medical Center,
Bronx, NY

For Dr. Piña's biography, click here


Faculty Panelists

Kirkwood F. Adams, Jr., MD
Associate Professor of Medicine and Radiology,
Division of Cardiology, University of North Carolina at Chapel Hill,
Chapel Hill, NC

For Dr. Adams's biography, click here


James L. Januzzi, Jr., MD, FACC, FESC
Hutter Family Professor of Medicine in the Field of Cardiology,
Massachusetts General Hospital, Boston, MA;
Faculty, Harvard Clinical Research Institute, Boston, MA

For Dr. Januzzi's biography, click here


Content Planning

Dr. Fleming serves as Chief Medical Officer of Antidote Education Company. He is a Clinical Associate Professor of Family Medicine at LSU Health Science Center in Shreveport, and Clinical Assistant Professor of Family and Community Medicine at Tulane University School of Medicine. Dr. Fleming has more than 29 years of medical field experience and is past President of the American Academy of Family Physicians and the Louisiana Academy of Family Physicians; and was founding President of the Louisiana Health Care Quality Forum. Dr. Fleming also is chief medical officer for Amedisys Home Health Services.

Accreditation Statement

Antidote Education Company is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Antidote designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AAPA: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.

AANP: This program is approved for 0.75 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Program ID 1502079. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Disclosures of Conflicts of Interest

Antidote is committed to creating, developing, and operating high-quality, relevant, and practical continuing medical education activities that are in compliance with the ACCME's policies on commercial support and disclosure. Specifically, we are dedicated to ensuring that our events are planned and implemented free of the control of commercial interests and to identifying and resolving conflicts of interest of all persons in a position to control the content of an educational activity before the educational activity is delivered to our attendees. In addition, it is our standard practice to disclose all relevant financial relationships of our speakers in writing to our attendees before the beginning of an educational activity.

Individuals in a position to control the content of this CME activity reported the following relevant financial relationships with commercial interests:

William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE has disclosed the following relationships:
  • Grants/Research Support: National Institute of Health
  • Consultant: Abbott Vascular, ARCA biopharma, CardioKinetix, Inc., Cardiorentis, CVRx, Intersection Medical, Novartis, Respicardia, St.Jude Medical, Sunshine Heart
  • Advisory Board: Abbott Vascular, Global Cardiovascular Innovations Center, Respicardi, Zoll
  • Editorial Board: Congestive Heart Failure, Expert Review of Cardiovascular Therapy, European Heart Journal, JACC-Heart Failure, Journal Watch Cardiology, PACE – Pacing and Clinical Electrophysiology, Reviews in Cardiovascular Medicine, The American Heart Hospital Journal, The Journal of Heart Failure
Kirkwood F. Adams, Jr., MD has disclosed the following relationships:
  • Grants/Research Support: Amgen, Cardiorentis, Novartis, Otsuka, Roche Diagnostics
James L. Januzzi, Jr., MD, FACC, FESC has disclosed the following relationships:
  • Grants/Research Support: Roche Diagnostics, Siemens
  • Consultant: Critical Dx, Novartis, Roche Diagnostics
  • Other: Boehringer Ingelheim (CEC), Novartis (CEC)
Ileana L. Piña, MD, MPH has disclosed the following relationships:
  • Grants/Research Support: GE Healthcare
  • Consultant: Novartis

All Antidote staff members and others involved in the planning, development and review of the content of this activity have no relevant conflicts of interest to disclose.

Specifically, the following individuals have disclosed no conflicts of interest:

  • Michael O. Fleming, MD FAAFP (Course Director)
  • Shanna McClennen (Editor)
  • Matthew Fleming (Vice President, Antidote Education Company)

Instructions for Participation and Credit

  • Read the learning objectives and faculty disclosures.
  • Click on the link below to participate in the online activity. Answer any polling questions presented.
  • Complete the post-test and evaluation presented at the end of the activity.

A statement of credit will be issued automatically upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. You will have 3 opportunities to successfully complete the post-test. After completing the course evaluation click the link you are presented with to return to claim your statement of credit.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclosure of Unlabeled Use

All faculty have indicated that this enduring material does not include the off-label/investigational use of a commercial product or device.


The material presented in this course is being made available by Antidote Education Company and ArcheMedX for educational purposes only. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement or opinion of the faculty which may be helpful to others who face similar situations. Opinions expressed in this activity are those of the faculty and not of Antidote.

Every effort has been made to assure the accuracy of the data presented at this course. Physicians may care to check specific details such as drug doses and contraindications in standard sources prior to clinical application.

Privacy Policy

Please read Antidote's Privacy Policy at If you have questions about this CME activity, please call Antidote at 888-692-2631 or send an e-mail to